Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Other Non-Current Liabilities (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $29000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities changed 0.0% to $29000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29000.0 through Dec 2025, changed 0.0% year-over-year, with the annual reading at $29000.0 for FY2025, 0.0% changed from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $29000.0 at Centessa Pharmaceuticals, roughly flat from $29000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $43000.0 in Q2 2022, with the low at $29000.0 in Q4 2023.
  • Average Other Non-Current Liabilities over 4 years is $30400.0, with a median of $29000.0 recorded in 2023.
  • Peak annual rise in Other Non-Current Liabilities hit 0.0% in 2024, while the deepest fall reached 0.0% in 2024.
  • Over 4 years, Other Non-Current Liabilities stood at $43000.0 in 2022, then plummeted by 32.56% to $29000.0 in 2023, then changed by 0.0% to $29000.0 in 2024, then changed by 0.0% to $29000.0 in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $29000.0, $29000.0, and $29000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.